[Alfa-blockade with doxazosin vs tamsulozin in combination of intermittent androgen blockade in patients with prostate cancer].
We have studied the efficacy of Alfa-blockade with Doxazosin vs Tamsulozin in combination with Intermittent Androgen Blockade (IAB) in patients with low grade prostate cancer. Our clinical trial included: I group (n=15) of patients who received doxazosin with IAB and flutamide; II group (n=13) of patients who received tamsulozin in combination with IAB and flutamide and III (n=33) group with flutamid monotherapy alone. Our results have shown that the combination of doxasozin and IAB with the flutamide leads to the better improvement of uroflowmetry and IPSS parameters, whereas the tamsulozin and IAB with flutamide combination induce those improvements for the longer period during the disease remission.
Muradian
A A
AA
Department of Urology, Yerevan State Medical University, Armenia.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017292:Doxazosin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005485:Flutamide / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013449:Sulfonamides / Q000627:therapeutic use*; D000077409:Tamsulosin; D014563:Urodynamics / Q000502:physiology
D000317:Adrenergic alpha-Antagonists; D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D013449:Sulfonamides; D005485:Flutamide; D000077409:Tamsulosin; D017292:Doxazosin